AcouSort (ACOU) Q4 2025 earnings summary

Executive summary

• Ended 2025 with strong commercial momentum, expanding partnerships, and validated technology for automated sample processing in diagnostics and cell therapy.

• Net sales for the year increased 45% year-over-year to TSEK 6,853, driven by higher license fees and product sales.

• Multiple new collaborations and contracts signed in Q4, including with SeeQ Diagnostics, MFX, and University of Wisconsin-Madison.

• Successful SEK 24.9 million rights issue in 2025 strengthened financial position and secures funding into 2027.

Financial highlights

• Q4 2025 net sales: TSEK 2,459 (up from 1,221 in Q4 2024); full-year net sales: TSEK 6,853 (up from 4,737 in 2024).

• Q4 result before tax: TSEK -2,623 (improved from -2,829); full-year result before tax: TSEK -12,145 (improved from -15,078).

• Result per share for 2025: SEK -0.64 (improved from -1.01 in 2024).

• Equity ratio at year-end: 91% (up from 69% in 2024); cash and cash equivalents: TSEK 6,291.

Outlook and guidance

• Positioned to transition from technology validation to commercial scale-up in 2026.

• Goal for 2026/27: convert exploratory collaborations into long-term OEM agreements for scalable, recurring revenue.

• Funding secured for critical OEM-driven development program and operations into 2027.